clinical trial · NCT07005128
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small-cell Lung CancerExtensive Stage Small-cell Lung CancerTarlatamabDurvalumabCarboplatinEtoposide
brief summary
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
started
Aug 18, 2025
primary completion
Jan 4, 2029
completion
Jul 15, 2029
last updated
May 5, 2026
official title
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol